Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BHMT | Q93088 | 11/20 | 0.67 |
| ▸ | BHMT2 | Q9H2M3 | 1/20 | 0.67 |
| ▸ | NOS2 | P35228 | 2/20 | 0.61 |
| ▸ | NOS3 | P29474 | 1/20 | 0.61 |
| ▸ | NOS1 | P29475 | 1/20 | 0.61 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.47 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.47 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.47 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.47 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2119412 | 1.00 | BHMT (0.67) | BHMTBHMT2NOS2NOS3NOS1 | |
| SCHEMBL474910 | 1.00 | BHMT (0.67) | BHMTBHMT2NOS2NOS3NOS1 | |
| Hydrochloric Acid SCHEMBL28941785 | 0.98 | BHMT (0.65) | BHMTBHMT2NOS2NOS3NOS1 | |
| SCHEMBL5904145 | 0.91 | BHMT (0.57) | BHMTBHMT2NOS2NOS3NOS1 | |
| SCHEMBL1031684 | 0.89 | BHMT (0.76) | BHMTBHMT2NOS2NOS3NOS1 | |
| SCHEMBL27791649 | 0.89 | BHMT (0.76) | BHMTBHMT2NOS2NOS3NOS1 | |
| SCHEMBL21851894 | 0.89 | BHMT (0.76) | BHMTBHMT2NOS2NOS3NOS1 | |
| SCHEMBL1031686 | 0.89 | BHMT (0.76) | BHMTBHMT2NOS2NOS3NOS1 | |
| SCHEMBL1158177 | 0.88 | BHMT (0.56) | BHMTBHMT2NOS2NOS3NOS1 | |
| SCHEMBL1285565 | 0.88 | BHMT (0.66) | BHMTBHMT2NOS2NOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190119322-A1 | PREPARATION OF FUNCTIONAL HOMOCYSTEINE RESIDUES IN POLYPEPTIDES AND PEPTIDES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-04-25 | — | — | US | claimed |
| WO-2018128826-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS | CIDARA THERAPEUTICS, INC. (US) | 2018-07-12 | — | — | WO | claimed |
| WO-2018006063-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS | CIDARA THERAPEUTICS, INC. (US) | 2018-01-04 | — | — | WO | claimed |
| WO-2017189860-A1 | PREPARATION OF FUNCTIONAL HOMOCYSTEINE RESIDUES IN POLYPEPTIDES AND PEPTIDES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-11-02 | — | — | WO | claimed |
| US-20120093726-A1 | Radiolabeled Fluorine Derivatives of Methionine | CRC FOR BIOMEDICAL IMAGING DEVELOPMENT LTD. (AU) | 2012-04-19 | — | — | US | claimed |
| EP-2411360-A1 | RADIOLABELED FLUORINE DERIVATIVES OF METHIONINE | CRC For Biomedical Imaging Development Ltd (AU) | 2012-02-01 | — | — | EP | claimed |
| WO-2010108210-A1 | RADIOLABELED FLUORINE DERIVATIVES OF METHIONINE | CRC FOR BIOMEDICAL IMAGING DEVELOPMENT LTD (AU) | 2010-09-30 | — | — | WO | claimed |
| US-12540162-B2 | Preparation of functional homocysteine residues in polypeptides and peptides | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-02-03 | — | — | US | disclosed |
| US-20240092833-A1 | PREPARATION OF FUNCTIONAL HOMOCYSTEINE RESIDUES IN POLYPEPTIDES AND PEPTIDES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-03-21 | — | — | US | disclosed |
| US-11732008-B2 | Preparation of functional homocysteine residues in polypeptides and peptides | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-22 | — | — | US | disclosed |
| US-20230190950-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230165970-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2023-06-01 | — | — | US | disclosed |
| US-20190119322-A1 | PREPARATION OF FUNCTIONAL HOMOCYSTEINE RESIDUES IN POLYPEPTIDES AND PEPTIDES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-04-25 | — | — | US | disclosed |
| US-20120093726-A1 | Radiolabeled Fluorine Derivatives of Methionine | CRC FOR BIOMEDICAL IMAGING DEVELOPMENT LTD. (AU) | 2012-04-19 | — | — | US | disclosed |
| US-20120093726-A1 | Radiolabeled Fluorine Derivatives of Methionine | CRC FOR BIOMEDICAL IMAGING DEVELOPMENT LTD. (AU) | 2012-04-19 | — | — | US | disclosed |
| EP-2411360-A1 | RADIOLABELED FLUORINE DERIVATIVES OF METHIONINE | CRC For Biomedical Imaging Development Ltd (AU) | 2012-02-01 | — | — | EP | disclosed |
| EP-2411360-A1 | RADIOLABELED FLUORINE DERIVATIVES OF METHIONINE | CRC For Biomedical Imaging Development Ltd (AU) | 2012-02-01 | — | — | EP | disclosed |
| JP-2011024454-A | METHOD FOR PRODUCING S-POSITION-SUBSTITUTED CYSTEINE DERIVATIVE AND/OR S-POSITION-SUBSTITUTED HOMOCYSTEINE DERIVATIVE BY FERMENTATION METHOD | EIKODO HONTEN:KK | 2011-02-10 | — | — | JP | disclosed |
| WO-2010108210-A1 | RADIOLABELED FLUORINE DERIVATIVES OF METHIONINE | CRC FOR BIOMEDICAL IMAGING DEVELOPMENT LTD (AU) | 2010-09-30 | — | — | WO | disclosed |
| WO-2010108210-A1 | RADIOLABELED FLUORINE DERIVATIVES OF METHIONINE | CRC FOR BIOMEDICAL IMAGING DEVELOPMENT LTD (AU) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119322-A1 | PREPARATION OF FUNCTIONAL HOMOCYSTEINE RESIDUES IN POLYPEPTIDES AND PEPTIDES | BHMT2, BHMT, PTMS | BHMT 2/4885BHMT2 1/4885NOS2 477/4885 |
| US-20120093726-A1 | Radiolabeled Fluorine Derivatives of Methionine | BHMT2, MGMT, AHCY | BHMT 8/4885BHMT2 1/4885NOS2 3783/4885 |
| US-12540162-B2 | Preparation of functional homocysteine residues in polypeptides and peptides | PTMS, AHCY, BHMT2 | BHMT 9/4885BHMT2 3/4885NOS2 630/4885 |
| US-20230190950-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS | FCGR3B, FCGR1A, FCGR2A | BHMT 3190/4885BHMT2 3128/4885NOS2 2263/4885 |
| US-11732008-B2 | Preparation of functional homocysteine residues in polypeptides and peptides | BHMT2, BHMT, PTMS | BHMT 2/4885BHMT2 1/4885NOS2 477/4885 |
| US-20230165970-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS | FCGR3B, FCGR1A, FCGR2A | BHMT 3190/4885BHMT2 3128/4885NOS2 2263/4885 |
| US-20240092833-A1 | PREPARATION OF FUNCTIONAL HOMOCYSTEINE RESIDUES IN POLYPEPTIDES AND PEPTIDES | BHMT2, BHMT, PTMS | BHMT 2/4885BHMT2 1/4885NOS2 477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.